• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND RESOLUTE ONYX RX; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND RESOLUTE ONYX RX; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Model Number RONYX25022UX
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Thrombus (2101); Patient Problem/Medical Problem (2688)
Event Date 10/23/2018
Event Type  Injury  
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
During the index procedure one resolute onyx des was implanted in the graft prox cx.Approximately 7 months later, a second resolute onyx des was implanted in a new lesion.Approximately 7 months later (and 14 months after the index procedure) two additional resolute onyx des were then implanted during a revascularization procedure.Approximately one month later (and 15 months post index procedure) svf to lcx vein graft thrombosis was reported.It was reported that the lcx was involved and that the thrombosis occurred in a resolute onyx des.The patient was hospitalized and received thrombectomy using a medtronic export ap expiration catheter.The patient recovered.The investigator assessed the event as not related to the device but possibly related to the antiplatelet medication.The patient recovered.
 
Manufacturer Narrative
The ae term was updated to coronary artery stent thrombosis.During the revascularization 7 months post index and the revascularization 14 months post index procedure, resolute onyx des were implanted to treat new lesions in the graft cx, these are consider to be target vessel revascularizations.If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
Additional information: cec adjudicated the stent thrombosis end point as late stent thrombosis arc defined.Graft 2nd obtuse marginal.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESOLUTE ONYX RX
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
091708734
MDR Report Key8110319
MDR Text Key128582217
Report Number9612164-2018-03399
Device Sequence Number1
Product Code NIQ
UDI-Device Identifier00643169556829
UDI-Public00643169556829
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P160043
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 02/03/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/28/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date10/05/2019
Device Model NumberRONYX25022UX
Device Catalogue NumberRONYX25022UX
Device Lot Number0008824232
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/17/2020
Date Device Manufactured10/05/2017
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age65 YR
Patient Weight117
-
-